SG10202111623TA - Methods and compositions for treating sleep apnea - Google Patents
Methods and compositions for treating sleep apneaInfo
- Publication number
- SG10202111623TA SG10202111623TA SG10202111623TA SG10202111623TA SG10202111623TA SG 10202111623T A SG10202111623T A SG 10202111623TA SG 10202111623T A SG10202111623T A SG 10202111623TA SG 10202111623T A SG10202111623T A SG 10202111623TA SG 10202111623T A SG10202111623T A SG 10202111623TA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- sleep apnea
- treating sleep
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491504P | 2017-04-28 | 2017-04-28 | |
| US201762558814P | 2017-09-14 | 2017-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202111623TA true SG10202111623TA (en) | 2021-12-30 |
Family
ID=63918622
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909973U SG11201909973UA (en) | 2017-04-28 | 2018-04-26 | Methods and compositions for treating sleep apnea |
| SG10202111623TA SG10202111623TA (en) | 2017-04-28 | 2018-04-26 | Methods and compositions for treating sleep apnea |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909973U SG11201909973UA (en) | 2017-04-28 | 2018-04-26 | Methods and compositions for treating sleep apnea |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11123313B2 (en) |
| EP (1) | EP3615016A4 (en) |
| JP (2) | JP7373997B2 (en) |
| KR (2) | KR20190140019A (en) |
| CN (1) | CN110799181A (en) |
| AU (2) | AU2018260666B2 (en) |
| BR (1) | BR112019022483A2 (en) |
| CA (1) | CA3061468A1 (en) |
| CO (1) | CO2019013180A2 (en) |
| CR (1) | CR20190546A (en) |
| DO (1) | DOP2019000274A (en) |
| EC (1) | ECSP19084058A (en) |
| GE (2) | GEP20247617B (en) |
| MA (1) | MA49069A (en) |
| MX (2) | MX2019012729A (en) |
| MY (1) | MY200172A (en) |
| NI (1) | NI201900110A (en) |
| PH (1) | PH12019502427A1 (en) |
| SG (2) | SG11201909973UA (en) |
| UA (1) | UA127759C2 (en) |
| WO (1) | WO2018200775A1 (en) |
| ZA (1) | ZA201907158B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019012729A (en) * | 2017-04-28 | 2019-12-19 | Brigham & Womens Hospital Inc | Methods and compositions for treating sleep apnea. |
| WO2019152475A1 (en) * | 2018-01-30 | 2019-08-08 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| CN108309261B (en) * | 2018-02-11 | 2020-05-22 | 西安交通大学 | Sudden death early warning method, device and system |
| US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| CN112930179A (en) * | 2018-10-31 | 2021-06-08 | 爱普宁公司(特拉华) | Methods and compositions for treating sleep apnea |
| CN113692277A (en) | 2019-02-08 | 2021-11-23 | 布里格姆妇女医院 | Methods and compositions for treating sleep apnea |
| US20220362221A1 (en) * | 2019-11-04 | 2022-11-17 | Apnimed, Inc. (Delaware) | Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea |
| RU2757470C1 (en) * | 2020-11-19 | 2021-10-18 | Ренат Рашитович Ахмеров | Method for treatment of snoring with introduction of trombocytic autologous plasma |
| WO2022155162A1 (en) * | 2021-01-14 | 2022-07-21 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| AU2022231133A1 (en) * | 2021-03-04 | 2023-09-21 | Apnimed, Inc. (Delaware) | Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea |
| EP4322930A1 (en) * | 2021-04-16 | 2024-02-21 | Apnimed, Inc. (Delaware) | Combination of a norepinephrine reuptake inhibitor and a cannabinoid for use in treating sleep apnea |
| IL309251A (en) * | 2021-06-17 | 2024-02-01 | Apnimed Inc Delaware | Norepinephrine reuptake inhibitors for treating sleep apnea |
| KR20240053061A (en) * | 2021-08-31 | 2024-04-23 | 애프니메드, 인코포레이티드 (델라웨어) | Methods and compositions for treating sleep apnea |
| TW202342033A (en) | 2021-12-22 | 2023-11-01 | 德商拜耳廠股份有限公司 | Combination of an α2-adrenoceptor subtype c (alpha-2c) antagonist with a norepinephrine reuptake inhibitor for the treatment of sleep apnea |
| WO2023118126A1 (en) * | 2021-12-22 | 2023-06-29 | Bayer Aktiengesellschaft | Combination of a task1/3 channel blocker with a norepinephrine reuptake inhibitor for the treatment of sleep apnea |
| TW202342011A (en) | 2021-12-22 | 2023-11-01 | 德商拜耳廠股份有限公司 | Combination of an α2-adrenoceptor subtype c (alpha-2c) antagonists with a muscarinic receptor antagonist for the treatment of sleep apnea |
| WO2023219991A1 (en) * | 2022-05-13 | 2023-11-16 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1191930A2 (en) | 1999-05-20 | 2002-04-03 | Sepracor Inc. | Methods for treatment of asthma using s-oxybutynin |
| MXPA02008183A (en) * | 2000-02-24 | 2002-11-29 | Upjohn Co | New drug combinations. |
| US20060039866A1 (en) * | 2004-08-20 | 2006-02-23 | Cypress Bioscience, Inc. | Method for treating sleep-related breathing disorders |
| US8512751B2 (en) * | 2004-12-20 | 2013-08-20 | Collegium Pharmaceutical, Inc. | Pharmaceutical compositions for sleep disorders |
| US8753327B2 (en) * | 2011-01-28 | 2014-06-17 | Pfantastic Medical Research Institute, Llc | Methods for treating obstructive sleep apnea |
| MX2019012729A (en) * | 2017-04-28 | 2019-12-19 | Brigham & Womens Hospital Inc | Methods and compositions for treating sleep apnea. |
| WO2019152475A1 (en) * | 2018-01-30 | 2019-08-08 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
-
2018
- 2018-04-26 MX MX2019012729A patent/MX2019012729A/en unknown
- 2018-04-26 WO PCT/US2018/029518 patent/WO2018200775A1/en active Application Filing
- 2018-04-26 KR KR1020197034523A patent/KR20190140019A/en active IP Right Grant
- 2018-04-26 CA CA3061468A patent/CA3061468A1/en active Pending
- 2018-04-26 US US16/609,048 patent/US11123313B2/en active Active
- 2018-04-26 SG SG11201909973U patent/SG11201909973UA/en unknown
- 2018-04-26 AU AU2018260666A patent/AU2018260666B2/en active Active
- 2018-04-26 MA MA049069A patent/MA49069A/en unknown
- 2018-04-26 GE GEAP201815757A patent/GEP20247617B/en unknown
- 2018-04-26 BR BR112019022483-1A patent/BR112019022483A2/en unknown
- 2018-04-26 JP JP2019558554A patent/JP7373997B2/en active Active
- 2018-04-26 GE GEAP201815226A patent/GEP20227387B/en unknown
- 2018-04-26 EP EP18791670.5A patent/EP3615016A4/en active Pending
- 2018-04-26 CR CR20190546A patent/CR20190546A/en unknown
- 2018-04-26 CN CN201880042623.1A patent/CN110799181A/en active Pending
- 2018-04-26 KR KR1020247009759A patent/KR20240042261A/en not_active Application Discontinuation
- 2018-04-26 UA UAA201910615A patent/UA127759C2/en unknown
- 2018-04-26 MY MYPI2019006319A patent/MY200172A/en unknown
- 2018-04-26 SG SG10202111623TA patent/SG10202111623TA/en unknown
-
2019
- 2019-10-24 MX MX2022010349A patent/MX2022010349A/en unknown
- 2019-10-25 PH PH12019502427A patent/PH12019502427A1/en unknown
- 2019-10-25 NI NI201900110A patent/NI201900110A/en unknown
- 2019-10-25 DO DO2019000274A patent/DOP2019000274A/en unknown
- 2019-10-29 ZA ZA2019/07158A patent/ZA201907158B/en unknown
- 2019-11-25 EC ECSENADI201984058A patent/ECSP19084058A/en unknown
- 2019-11-26 CO CONC2019/0013180A patent/CO2019013180A2/en unknown
-
2021
- 2021-09-10 US US17/471,892 patent/US20210401777A1/en not_active Abandoned
-
2022
- 2022-09-27 AU AU2022241471A patent/AU2022241471A1/en active Pending
-
2023
- 2023-06-30 JP JP2023108387A patent/JP2023139000A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201907158B (en) | Methods and compositions for treating sleep apnea | |
| HK1258205A1 (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| IL276247A (en) | Methods and compositions for treating sleep apnea | |
| IL271503A (en) | Sleep disorder compositions and treatments thereof | |
| EP3092033A4 (en) | Method and apparatus for treating sleep apnea | |
| PL3253443T3 (en) | Apparatus for treatment of snoring and sleep apnoea | |
| IL269490B (en) | Surface treatment methods and compositions therefor | |
| IL246537A0 (en) | Device and method for sleep apnoea treatment | |
| HK1258696A1 (en) | Novel compositions and methods for treating or preventing dermal disorders | |
| IL285197A (en) | Methods and compositions for treating sleep apnea | |
| IL269637A (en) | Compositions and methods for treating synucleinopathies | |
| HK1251168A1 (en) | Arenaviruses for use in the treatment and/or prevention of tumors and method for producing arenaviruses with (improved) tumor-regression properties | |
| EP3866736A4 (en) | Methods and devices for treating sleep apnea | |
| EP3148488A4 (en) | Oral appliance for treating sleep apnea | |
| IL269743A (en) | Methods and compositions for treating retina-associated disease using ccr3-inhibitors | |
| PT3691649T (en) | Compositions and methods for wound treatment | |
| IL269550A (en) | Compositions and methods for treating synucleinopathies | |
| IL251880A0 (en) | Compositions for treating acute, post-operative, or chronic pain and methods of using the same | |
| HK1255695A1 (en) | Composition and methods for the treatment of blepharoptosis | |
| IL260929B (en) | Dental appliance system and method of forming thereof for treating sleep apnea | |
| ZA202002526B (en) | New alcoxyamino derivatives for treating pain and pain related conditions | |
| IL261984B (en) | Sultiame for the treatment of sleep apnea | |
| IL235257A (en) | System for preventing snoring and sleep apnea | |
| EP3624808A4 (en) | Methods and compositions for improving sleep | |
| HK1255631A1 (en) | Pharmaceutical composition for preventing and treating sleep disorders |